实用老年医学 ›› 2023, Vol. 37 ›› Issue (11): 1176-1180.doi: 10.3969/j.issn.1003-9198.2023.11.024
蔡佳, 王琳, 樊卫飞
收稿日期:2023-01-28
出版日期:2023-11-20
发布日期:2023-11-22
通讯作者:
樊卫飞,Email:fwfei1974@njmu.edu.cn
基金资助:
Received:2023-01-28
Online:2023-11-20
Published:2023-11-22
中图分类号:
蔡佳, 王琳, 樊卫飞. 老年非小细胞肺癌免疫治疗现状及进展[J]. 实用老年医学, 2023, 37(11): 1176-1180.
| [1] OWONIKOKO T K, RAGIN C C, BELANI C P, et al. Lung cancer in elderly patients:an analysis of the surveillance, epidemiology, and end results database[J]. J Clin Oncol, 2007, 25(35): 5570-5577. [2] DE GROOT P M, WU C C, CARTER B W, et al. The epidemiology of lung cancer[J]. Transl Lung Cancer Res, 2018, 7(3): 220-233. [3] SEZER A, KILICKAP S, GÜMÜŞ M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%:a multicentre, open-label, global, phase 3, randomised, controlled trial[J]. Lancet, 2021, 397(10274): 592-604. [4] HORN L, SPIGEL D R, VOKES E E, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase Ⅲ trials (CheckMate 017 and CheckMate 057)[J]. J Clin Oncol, 2017, 35(35): 3924-3933. [5] HERBST R S, GIACCONE G, DE MARINIS F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC[J]. N Engl J Med, 2020, 383(14): 1328-1339. [6] HERBST R S, BAAS P, KIM D W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial[J]. Lancet, 2016, 387(10027): 1540-1550. [7] MAGEE D E, HIRD A E, KLAASSEN Z, et al. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors:a systematic review and meta-analysis of randomized clinical trials[J]. Ann Oncol, 2020, 31(1): 50-60. [8] VINAY D S, RYAN E P, PAWELEC G, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies[J]. Semin Cancer Biol, 2015, 35(Suppl): S185-S198. [9] FERRARA R, NAIGEON M, AUCLIN E, et al. Circulating T-cell immunosenescence in patients with advanced non-small cell lung cancer treated with single-agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy[J]. Clin Cancer Res, 2021, 27(2): 492-503. [10] FRASCA D, DIAZ A, ROMERO M, et al. B cell immunosenescence[J]. Annu Rev Cell Dev Biol, 2020, 36: 551-574. [11] BALDINI C, MARTIN ROMANO P, VOISIN A L, et al. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies[J]. Eur J Cancer, 2020, 129: 71-79. [12] HELLMANN M D, CIULEANU T E, PLUZANSKI A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22): 2093-2104. [13] WHERRY E J, KURACHI M. Molecular and cellular insights into T cell exhaustion[J]. Nat Rev Immunol, 2015, 15(8): 486-499. [14] BORGHAEI H, PAZ-ARES L, HORN L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639. [15] RITTMEYER A, BARLESI F, WATERKAMP D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (oak): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255-265. [16] RECK M, RODRíGUEZ-ABREU D, ROBINSON A G, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833. [17] CHAMPIAT S, DERCLE L, AMMARI S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J]. Clin Cancer Res, 2017, 23(8): 1920-1928. [18] PAZ-ARES L, LUFT A, VICENTE D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21): 2040-2051. [19] GADGEEL S, RODRÍGUEZ-ABREU D, SPERANZA G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2020, 38(14): 1505-1517. [20] RECK M, MOK T S K, NISHIO M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with egfr mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respir Med, 2019, 7(5): 387-401. [21] WEST H, MCCLEOD M, HUSSEIN M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(7): 924-937. [22] SGAMBATO A, CASALUCE F, GRIDELLI C. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly[J]. Expert Opin Biol Ther, 2017, 17(5): 565-571. [23] PAZ-ARES L, CIULEANU T E, COBO M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(2): 198-211. [24] REN S, XIONG X, YOU H, et al. The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer[J]. Front Immunol, 2021, 12: 689132. [25] RECKAMP K L, REDMAN M W, DRAGNEV K H, et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-map s1800a[J]. J Clin Oncol, 2022, 40(21): 2295-2306. [26] LV W, PEI X, ZHAO W, et al. Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer[J]. Transl Lung Cancer Res, 2022, 11(2): 201-212. [27] ALEXA T, ANTONIU S A, ALEXA I, et al. Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives[J]. Expert Rev Anticancer Ther, 2021, 21(3): 315-323. [28] LICHTENSTEIN M R L, NIPP R D, MUZIKANSKY A, et al. Impact of age on outcomes with immunotherapy in patients with non-small cell lung cancer[J]. J Thorac Oncol, 2019, 14(3): 547-552. [29] RODRÍGUEZ-ABREU D, POWELL S F, HOCHMAIR M J, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous nsclc: protocol-specified final analysis from KEYNOTE-189[J]. Ann Oncol, 2021, 32(7): 881-895. [30] MUCHNIK E, LOH K P, STRAWDERMAN M, et al. Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung cancer[J]. J Am Geriatr Soc, 2019, 67(5): 905-912. [31] GOMES F, LORIGAN P, WOOLLEY S, et al. A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients-the elders study[J]. ESMO Open, 2021, 6(1): 100042. [32] GARCIA M V, AGAR M R, SOO W K, et al. Screening tools for identifying older adults with cancer who may benefit from a geriatric assessment: a systematic review[J]. JAMA Oncol, 2021, 7(4): 616-627. [33] MORAD G, HELMINK B A, SHARMA P, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade[J]. Cell, 2021, 184(21): 5309-5337. [34] ALPERT A, PICKMAN Y, LEIPOLD M, et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring[J]. Nat Med, 2019, 25(3): 487-495. |
| [1] | 周坚, 谈谈. 肋间神经阻滞麻醉可减轻老年胸膜下肺肿瘤病人微波消融术中的疼痛[J]. 实用老年医学, 2024, 38(5): 509-437. |
| [2] | 宋海涛, 万昭君, 孟令新. Ⅲ期肺腺癌病人合并COVID-19后出现EML4-ALK融合基因1例报告并文献复习[J]. 实用老年医学, 2024, 38(2): 205-209. |
| [3] | 王天, 叶劲军, 李慧, 时书童, 张治, 周国仁, 王强, 张熔熔, 何侠. 免疫巩固治疗前NLR、PLR与Ⅲ期老年非小细胞肺癌病人预后的相关性[J]. 实用老年医学, 2023, 37(11): 1120-1124. |
| [4] | 袁艺丹, 刘增, 卢锡华. 格隆溴铵对老年肺癌根治术病人肺功能和肺内分流的影响[J]. 实用老年医学, 2023, 37(7): 662-666. |
| [5] | 刁文雅, 刘青, 孟琳慧, 苏运超, 李利亚. 超高龄小细胞肺癌合并慢性肾衰竭免疫治疗1例并文献复习[J]. 实用老年医学, 2023, 37(4): 422-423. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
|
